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The molecular mechanisms underlying the cellular uptake of long-chain fatty acids and the regulation of
this process have been elucidated in appreciable detail in the last decades. Two main players in this field,
each discovered in the early 1990s, are (i) a membrane-associated protein first identified in adipose (‘fat’)
tissue and referred to as putative fatty acid translocase (FAT)/CD36 (now officially designated as SR-B2)
which facilitates the transport of fatty acids across the plasma membrane, and (ii) the family of tran-
scription factors designated peroxisome proliferator-activated receptors (PPARa, PPARg, and PPARb/d) for
which fatty acids and fatty acid metabolites are the preferred ligand. CD36/SR-B2 is the predominant
membrane protein involved in fatty acid uptake into intestinal enterocytes, adipocytes and cardiac and
skeletal myocytes. The rate of cellular fatty acid uptake is regulated by the subcellular vesicular recycling
of CD36/SR-B2 from endosomes to the plasma membrane. Fatty acid-induced activation of PPARs results
in the upregulation of the expression of genes encoding various proteins and enzymes involved in
cellular fatty acid utilization. Both CD36/SR-B2 and the PPARs have been implicated in the derangements
in fatty acid and lipid metabolism occurring with the development of pathophysiological conditions,
such as high fat diet-induced insulin resistance and diabetic cardiomyopathy, and have been suggested as
targets for metabolic intervention. In this brief review we discuss the discovery and current under-
standing of both CD36/SR-B2 and the PPARs in metabolic homeostasis.
© 2016 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights
reserved.1. Introduction
Long-chain fatty acids (for convenience referred to as ‘fatty
acids’) are a group of nutritional compounds that serve pivotal roles
in various functions of the body. Fatty acids are (i) a main fuel for
cellular energy production, especially in liver, muscle and heart, (ii)
are part of phospholipids constituting biological membranes, (iii)
may covalently be attached to specific proteins to regulate their
function, and (iv) act in selected signal transduction events, for
example in fat taste perception or in regulation of protein phos-
phorylation, and (v) to modify gene expression. In addition, storage. Grimaldi who was involved
embrane fatty acid transport
t elucidating the functioning
etabolism as main research
C. Glatz).
de Biochimie et Biologie Moléculof fatty acids as part of triacylglycerols in adipose tissue is an effi-
cient form of creating a reserve energy source. Because of their
amphipathic nature, fatty acids also may exert detergent-like ac-
tivities such as causing (acute) cellular injury. In addition, this
physicochemical nature of fatty acids limits their aqueous solubility
and, therefore, dictates specific requirements to their presence and
transport in aqueous compartments [1]. In blood plasma and the
interstitium fatty acids are avidly bound by albumin (68 kDa) or are
present as fatty esters in lipoproteins. Intracellularly, fatty acids are
bound by (tissue-specific) cytoplasmic fatty acid-binding proteins
(FABPc, 14e15 kDa), which act as an intracellular counterpart of
plasma albumin [2,3]. How fatty acids traverse the plasma mem-
brane to enter the soluble cytoplasm, however, is not yet fully
understood. Specifically, there is debate on the rate-limiting step in
the overall fatty acid uptake process and if, and to what extent, one
or more membrane-associated proteins could facilitate and/or
regulate cellular fatty acid uptake [4e9].
A major contribution to our current understanding of cellular




CD36 cluster of differentiation 36
C/EBPa CCAAT/enhancer-binding protein a
DHA docosahexaenoic acid (22:6 ne3)
EPA eicosapentaenoic acid (20:5 ne3)
FAAR fatty acid-activated receptor
FABPc cytoplasmic fatty acid-binding protein
FABPpm plasma membrane fatty acid-binding protein
FAT (putative) fatty acid translocase (CD36/SR-B2)
FATP fatty acid-transport protein
GLUT4 glucose transporter-4
HIF-1 hypoxia-inducible factor-1
PPAR peroxisome proliferator-activated receptor
PPRE peroxisome proliferator-activated receptor
response element
RXR retinoid X receptor
SR-B2 scavenger receptor B2
VAMP vesicle-associated membrane protein
v-ATPase vacuolar-type Hþ-ATPase
J.F.C. Glatz, J.J.F.P. Luiken / Biochimie 136 (2017) 21e2622(1956e2016) [10]. Studying fatty acid homeostasis in adipose tis-
sue, he discovered in 1992 that fatty acid uptake into adipose cells is
important for adipogenesis, especially through fatty acid-induced
expression of aP2 (the adipocyte-specific FABPc) [11]. Subse-
quently, in 1993 Dr. Nada Abumrad together with Dr. Raafat el-
Maghrabi (at that time in Stony Brook, NY, U.S.A.) cloned the pro-
tein implicated in adipocyte fatty acid uptake identifying it as the
multifunctional membrane protein CD36 (now officially designated
as scavenger receptor B2, SR-B2; Ref. [12]). Dr. Grimaldi together
with Dr. Ez-Zoubir Amri contributed to this work by establishing
that CD36/SR-B2 is crucial for preadipocyte differentiation [13]. In
the present short reviewwewill focus on the discovery of CD36/SR-
B2 as ‘putative membrane fatty acid translocase’ (FAT) and its
involvement in fatty acid metabolism in both physiological and
pathophysiological conditions.2. Mechanism of cellular fatty acid uptake: historical
perspective
From the early 1980s onwards there has been dispute as to the
involvement, or not, of membrane-associated proteins in the up-
take of fatty acids by parenchymal cells. Several researchers re-
ported cellular fatty acid uptake to show saturation kinetics, to be
sensitive to universal inhibitors of protein-mediated plasma
membrane transport processes such as phloretin, and to be sensi-
tive to competitive inhibition. While these observations are in favor
of protein-mediated transmembrane fatty acid transport, it could
be argued that saturation of fatty acid transport can be explained
alternatively as saturation of metabolism in combination with
passive diffusional uptake [5]. In addition, the used inhibitors may
act on fatty acid uptake indirectly via effects on structural organi-
zation of the membrane bilayer, while the fatty acid competition
experiments may be explained by competition at the level of fatty
acid binding to albumin and/or FABPc rather than a membrane-
associated protein. From a physiological perspective, however,
having fatty acids moving in or out of cells without control at the
membrane would be undesirable as this may seriously hamper
coordination of intracellular availability of fatty acids withchanging metabolic needs [8].
Starting in the mid-1980s several groups reported on the
identification of peripheral and integral membrane proteins puta-
tively involved in the cellular uptake of fatty acids. These include
plasmamembrane fatty acid-binding protein (FABPpm; 40e43 kDa),
fatty acid transport proteins 1e6 (FATP1e6; 63 kDa), caveolin-1
(21e24 kDa), and fatty acid translocase (FAT; 88 kDa) [for review
14,15]. Of these, the FATP's were found to be enzymes, i.e., acyl-CoA
synthetases, and function in cellular fatty acid uptake by converting
incoming fatty acids directly into their acyl-CoA ester, resulting in
metabolic trapping of fatty acids [15]. With respect to nomencla-
ture it should be mentioned that, for convenience, these proteins
commonly are referred to as ‘fatty acid transporters’ despite the
remaining uncertainty as to the exact mechanism by which any of
these proteins participate in the fatty acid transport process within
the plasma membrane. After all, these proteins merely share the
feature of facilitating e not necessarily transporting e the trans-
membrane translocation of (long-chain) fatty acids.
Studies on fatty acid uptake into isolated rat adipocytes by
Abumrad and colleagues had revealed that prior incubation of the
cells with diisothiocyanodisulfonic acid (DIDS) or with sulfo-N-
succinimidyl derivates of long-chain fatty acids (in particular
oleate) led to a marked (about 70%) and irreversible inhibition of
the rate of fatty acid uptake [16,17]. Both inhibitors reacted cova-
lently with a membrane protein of about 85e88 kDa, suggesting
this protein to be involved in membrane permeation of (long-
chain) fatty acids. Subsequent cloning of this protein, then referred
to as putative fatty acid translocase (FAT), revealed it to be the rat
homologue of the transmembrane glycoprotein CD36 (cluster of
differentiation 36), a ubiquitous protein originally identified in
platelets [13]. CD36 is also identical to GP IIIb or PAS IV, a protein
that is enriched in the apical membranes of lipid-secreting mam-
mary cells during lactation. The role of FAT/CD36 in facilitating fatty
acid uptake by adipocytes was further supported by superimposed
time courses of FAT/CD36 expression and oleate uptake rates dur-
ing adipose differentiation, and by parallel induction of FAT/CD36
expression and oleate transport in preadipocytes following treat-
ment with the glucocorticoid dexamethasone [13]. This 1993-
publication by Abumrad, Grimaldi and colleagues served as a
landmark paper that initiated research into the role of FAT/CD36 in
fatty acid and lipid metabolism in health and disease, not only in
adipose tissue but also in other tissues in particular cardiac and
skeletal muscle [18]. Recently, the nomenclature of CD36 and of
other scavenger receptors with two transmembrane domains has
been standardized; CD36 now officially is designated as scavenger
receptor B2 (SR-B2) [12]. As a result, whereas the abbreviation FAT/
CD36 or just CD36 has been used in the literature from 1993 to
2015, the newly recommended designation is CD36/SR-B2.
Convincing evidence for a role of CD36/SR-B2 in cellular fatty
acid uptake was obtained when studying mice with a targeted
deletion of CD36/SR-B2. Compared to wild-type mice, CD36/SR-B2
knock-out mice showed reduced fatty acid uptake rates in vivo in
heart (50 to 80%), skeletal muscle (40 to 75%) and adipose
tissue (60 to 70%), but not in liver [19]. The latter is consistent
with the finding that in liver CD36/SR-B2 expression is absent or
very low [20]. These reductions in fatty acid uptake also contrib-
uted to altered rates of fatty acid metabolism, especially with re-
gard to fatty acid oxidation in working hearts and skeletal muscles
[21].
CD36/SR-B2 is currently known as the predominant membrane
protein facilitating fatty acid transport in adipocytes, enterocytes,
cardiac myocytes and skeletal myocytes [22e24]. With respect to
the molecular mechanism of cellular fatty acid uptake, at the
extracellular site CD36/SR-B2 most likely functions as an acceptor
for fatty acids to promote the partitioning of the fatty acids into the
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lipid rafts [25] (adsorption step). Subsequently, the fatty acids make
their way from the outer to the inner leaflet of the membrane, a
process referred to as ‘flip-flop’ (the polar carboxyl group of the
fatty acid moves through the bilayer interior and re-positions at the
opposite interface) (translocation step). This latter process occurs
very fast and would not need assistance from membrane proteins
[6]. At the inner site of the membrane the fatty acid will move into
the aqueous phase to be bound to cytoplasmic FABP (desorption
step). Desorption from the membrane has been suggested to be the
rate-limiting step of overall transmembrane transport [6]. At the
intracellular site CD36/SR-B2 may facilitate the transport by
providing a docking site for FABPc or for enzymes that act on fatty
acids such as acyl-CoA synthetase. Taken together, CD36/SR-B2 is
viewed to function in sequestering fatty acids in the membrane,
and help organize them within specific membrane domains (pre-
sumably lipid rafts) so as to make the fatty acids readily available
for subsequent aqueous transport and/or enzymic conversion
(Fig. 1). Interestingly, at the extracellular site CD36/SR-B2 shows
protein-protein interactionwith FABPpm, suggesting that clusters of
membrane proteins function in facilitating and modulating cellular
fatty acid uptake. In line with this, intracellularly the presence of
cytoplasmic FABP is required for proper functioning of CD36/SR-B2,
because transfection of CD36/SR-B2 in a rat heart muscle cell line
(H9c2) devoid of cytoplasmic FABP did not result in increased rates
of fatty acid uptake [26].
Whether CD36/SR-B2 would preferentially bind specific (long-
chain) fatty acid types has remained elusive. This is due, at least in
part, to the complexity of appropriate experimental approaches
which would need to consider a.o. differences among fatty acid
types in aqueous solubility and differences in interaction with
soluble proteins (such as albumin) and with biological membranes.Fig. 1. Schematic presentation of both the facilitatory and regulatory roles of CD36/SR-B2 in
rafts, CD36/SR-B2, most likely in interaction with the peripheral membrane protein FABPpm
(middle part of figure). Short-term regulation (i.e., minutes) of the rate of cellular fatty acid u
endosomal storage compartment to the sarcolemma, which is triggered by either changes
mediated by the AMPK-activated and insulin signaling cascades, respectively, which converg
via changes in CD36 gene transcription, mediated a.o. by fatty acid-induced PPAR activatioOf note, there is circumstantial evidence that the cellular uptake of
fatty acid species from marine oils, in particular eicosapentaenoic
acid (EPA, 20:5 ne3) and docosahexaenoic acid (DHA, 22:6 ne3),
also is facilitated by CD36/SR-B2 [1,27], suggesting that the bene-
ficial health effects of ne3 long-chain polyunsaturated fatty acids
are dependent on the sarcolemmal presence and proper func-
tioning of CD36/SR-B2.3. Short-term regulation of cellular fatty acid uptake by
CD36/SR-B2
Besides serving as a facilitator of transmembrane fatty acid
transport, CD36/SR-B2was found to be involved in the regulation of
the rate of cellular fatty acid uptake. This notion was triggered by
the observation that CD36/SR-B2 not only is present on the cell
membrane but also in intracellular compartments, notably endo-
somes. Regulation of fatty acid transport occurs by the reversible
translocation of CD36/SR-B2 from endosomes to the plasma
membrane to increase fatty acid uptake. For instance, in cardiac and
skeletal muscle, an increase in muscle contraction or the presence
of insulin each stimulate, within a fewminutes, the translocation of
CD36/SR-B2 from the endosomal compartment to the sarcolemma
which increases fatty acid uptake up to two-fold [28e30]. The
contraction-induced CD36/SR-B2 translocation is mediated by
AMP-activated kinase (AMPK). The insulin-induced translocation is
mediated by phosphoinositide 3 (PI3)-kinase [14]. Insulin and
contraction signaling operate independently to induce CD36
translocation, but converge at the level of the Rab GTPase-
activating protein AS160 via inactivating phosphorylation. This
leads to de-inhibition of Rab 8a, which is then allowed to use the
accelerated GDP/GTP cycling for the benefit of CD36 translocation
[31]. Remarkably, this mechanism of regulation of cellular fatty acid(long-chain) fatty acid uptake into cardiac and skeletal myocytes. At sarcolemmal lipid
and, at the intracellular site, with FABPc, facilitates the entry of fatty acids into the cell
ptake occurs by reversible intracellular recycling (vesicular transport) of CD36 from an
in the frequency of muscle contraction or by plasma insulin. These latter triggers are
e at AS160 (left part of figure). Long-term regulation of cellular fatty acid uptake occurs
n, HIF-1, and C/EBPa (right part of figure). See text for further explanation.
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known regulation of cellular glucose uptake which in cardiac and
skeletal muscle involves the translocation of the glucose trans-
porter GLUT4 from an intracellular storage depot to the sarco-
lemma [32]. Upon increased muscle contraction or insulin
stimulation, both CD36/SR-B2 and GLUT4 are recruited to the
sarcolemma within the same time frame resulting in increased
uptake rates for both fatty acids and glucose [14] (Fig. 1). CD36/SR-
B2 recycling has been confirmed to occur also in human skeletal
muscle [33,34] and in adipose tissue [35].
Current research is aimed at further deciphering the signaling
pathways, and vesicular trafficking and cytoskeletal network pro-
teins that control the short-term subcellular recycling of CD36/SR-
B2, especially in relation to that of GLUT4. For instance, it has been
reported that in cardiac muscle, specific vesicle-associated mem-
brane proteins (VAMPs) are necessary for both CD36/SR-B2 and
GLUT4 translocation while one isoform (VAMP4) is specifically
involved in CD36/SR-B2 traffic and another isoform (VAMP7) in
GLUT4 traffic [36]. More recently, the notion has arisen that the
facilitatory action of CD36/SR-B2 not only is controlled by intra-
cellular recycling of the protein but also by various types of post-
translational modification, in particular palmitoylation, N-glyco-
sylation and ubiquitination [37,38]. In addition, CD36/SR-B2 has
been proposed as target of O-linked N-acetylglucosamine (O-
GlcNac) which modification was observed to induce translocation
of CD36/SR-B2 to cardiac sarcolemma and subsequently increase
both the rate of myocellular fatty acid uptake and fatty acid
oxidation [39].
4. Transcriptional control of CD36/SR-B2 expression
The occurrence of CD36/SR-B2 in various tissues follows its role
as facilitator of fatty acid transport in tissues with a high capacity
for fatty acid metabolism, and fluctuates depending on develop-
mental, hormonal, and environmental conditions [40]. CD36/SR-B2
expression is high in segments of the intestine where most lipid
absorption occurs, in adipose tissue where fatty acids are stored in
neutral lipids, and in cardiac and (oxidative) skeletal muscle where
fatty acids constitute the main substrate for energy production.
CD36/SR-B2 is also found in endothelial cells, lung pneumocytes,
platelets, and macrophages, where its expression likewise has been
associated to fatty acid uptake and to binding of oxidized low-
density lipoproteins (oxLDL) [40].
CD36/SR-B2 expression is regulated by agonists of the nuclear
peroxisome proliferator-activated receptors (PPAR) in a tissue-
specific manner. PPARs are a family of transcription factors acti-
vated by a diversity of molecules including fatty acids and fatty acid
metabolites, and regulate the transcription of a large variety of
genes implicated in metabolism, inflammation, proliferation, and
differentiation in different cell types [41]. While PPARa is expressed
mostly in tissues exhibiting high rates of fatty acid oxidation (liver,
cardiac and skeletal muscle, kidney and brown adipose tissue) and
regulates the expression of proteins involved in fatty acid catabo-
lism, PPARg is expressed predominantly inwhite adipose tissue and
is a key regulator of adipogenesis. The third family member, PPARb/
d, shows a more widespread tissue distribution but in particular is
highly expressed in skeletal muscle during fasting and endurance
exercise [41]. PPARs can directly regulate the transcription of target
genes by forming a heterodimer with the retinoid X receptor (RXR)
and binding to peroxisome proliferator response element (PPRE)
sequences in the promotor- or transcribed-regions of target genes
through DNA binding domains [41].
It is noteworthy to mention that P.A. Grimaldi and Ez-Zoubir
Amri were the first to clone from preadipocytes the cDNA encod-
ing this third PPAR isoform [42]. Searching for a protein thatmediates transcriptional effects of fatty acids in preadipocytes, they
designated it accordingly as ‘fatty acid-activated receptor’ (FAAR).
Interestingly, during adipose differentiation FAAR expression is
induced markedly (2e4 days) earlier than that of PPARg [42]. Later
FAAR was renamed as PPARb (which, in turn, appeared identical to
PPARd). Although from a physiological perspective the term FAAR
would have been more appropriate for this entire subfamily of
nuclear receptors, Grimaldi's designation was not adopted, so that
the name PPAR remains to be in use for the three isoforms PPARa,
PPARg, and PPARb/d.
Fatty acids, especially long-chain fatty acids, are considered to
be the natural ligands for PPARs [43]. In addition, various fatty acid
metabolites, such as acyl-CoA esters, oxidized fatty acids and ei-
cosanoids, also activate PPARs [44]. Activation of PPARa in heart
and PPARb/d in skeletal muscle results in the coordinated increased
expression of various proteins and enzymes involved in mito-
chondrial b-oxidation of fatty acids, including an upregulation of
proteins involved in cellular fatty acid uptake, i.e., CD36/SR-B2 and
FABPc. In this way, by facilitating the entry and thus promoting the
intracellular availability of fatty acids CD36/SR-B2 positively in-
fluences its own de novo synthesis (feed-forward cycle) (Fig. 1). In
cardiac muscle the pivotal roles of both CD36/SR-B2 and the nu-
clear receptor PPARa in governing cardiac fatty acid utilization is
evident from the observations that (i) PPARa-null mice display a
decreased capacity of cardiac fatty acid utilization [45,46], (ii) car-
diac specific overexpression of PPARa in mice results in enhanced
fatty acid uptake and utilization [47], while (iii) deletion of CD36/
SR-B2 in PPARa-overexpressing mice prevents an increase in car-
diac fatty acid utilization [48].
Besides PPARs, also other transcriptional activators have been
implicated in the regulation of CD36/SR-B2 expression, including
CCAAT/enhancer-binding protein-a and hypoxia-inducible factor-1
(for review see Ref. [49]). The CD36/SR-B2 gene has a complicated
promoter structure with alternative transcription start sites [50].
Following the initial studies showing that the CD36/SR-B2 gene
promoter is regulated by PPARs [51,52], the subsequently reported
absence of PPRE in the upstream promoter region suggested that
transcriptional activation of the gene by PPAR ligands would be
indirectly dependent on PPAR [53]. However, in more recent
studies the PPRE sites have been identified and validated in the
distal part of the CD36/SR-B2 promoter [54,55].
5. CD36/SR-B2 and pathophysiology of lipid metabolism
Several chronic diseases are characterized by a perturbed fatty
acid or lipid metabolism. For instance, obesity is associated with
disturbances in the control of glucose and lipid metabolism
resulting in an atherogenic plasma lipid profile and deleterious
triacylglycerol accumulation in non-adipose tissues like liver, heart
and muscle (ectopic lipid accumulation). Consequently, obese in-
dividuals are at high risk of developing insulin resistance which
may further lead to type 2 diabetes and cardiovascular complica-
tions such as acute myocardial infarction and diabetic cardiomy-
opathy [56e58]. Because of its key role in the alterations in lipid
metabolism upon fatty acid oversupply, CD36/SR-B2 has been
implicated in the etiology of obesity-induced or high fat diet-
induced ectopic lipid accumulation and insulin resistance, and
has been suggested as target for therapeutic intervention [14,59].
The molecular mechanism whereby high fat diet induces lipid
accumulation in cardiac and skeletal muscle, and subsequently
insulin resistance and contractile dysfunction, has been unraveled
in much detail and shows a key role for CD36/SR-B2. Chronic
oversupply of fatty acids to the heart or muscle triggers changes in
the subcellular recycling of CD36/SR-B2 resulting in a permanent
re-location of this transporter from endosomes to the sarcolemma.
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the start of high fat feeding, and is accompanied by a concomitant
increase in the rate of myocellular fatty acid uptake [60]. Fatty acids
then not only become the main metabolic substrate for energy
production, but also lead to excess intramyocellular formation of
triacylglycerols, diacylglycerols and ceramides. The latter two fatty
acid metabolites inhibit insulin signaling and impair the trans-
location of glucose transporter GLUT4 from endosomes to the
sarcolemma, causing lowered glucose uptake and decreased
incorporation of glucose into glycogen. At that stage, the heart or
muscle has become insulin resistant and shows impaired contrac-
tile function [24,60]. In turn, this creates a vicious cycle of increased
fatty acid uptake, lipid-induced insulin resistance and further
impairment of cardiac function. In conclusion, CD36/SR-B2 plays an
essential role already in an early stage of the development of insulin
resistance due to lipid overload. Indeed, specific inhibition of CD36/
SR-B2 by sulfo-N-succinimidyl oleate [61] or deletion of CD36/SR-
B2 [62] protects against high fat diet-induced insulin resistance
and cardiac contractile dysfunction.
It has not yet been elucidated why increased fatty acid delivery
to heart or muscle results in a dysbalance of the subcellular recy-
cling of CD36/SR-B2 with most of the protein permanently residing
on the sarcolemma so that the rate of incoming fatty acids is not
tuned anymore to the metabolic needs of the myocyte. Recent
studies, however, suggest that increased CD36/SR-B2 translocation
to the sarcolemma is caused by alkalinization of endosomes due to
inhibition of the proton pumping activity of vacuolar-type Hþ-
ATPase (v-ATPse). Endosomal alkalinization was observed in rats
fed a high fat diet and appeared an early lipid-induced event pre-
ceding the onset of insulin resistance. The mechanism of lipid-
induced v-ATPase inhibition involves disassembly of the ATPase-
containing sub-complex (V1) from the membrane-bound proton
channel sub-complex (V0) and its subsequent migration into the
soluble cytoplasm [Y. Liu, J.J.F.P. Luiken, unpublished observations].
These new insights suggest that activation of endosomal v-ATPase
could be an effective approach to treat lipid-induced diabetic
cardiomyopathy.
6. Concluding remarks
In the last 25 years the notion has arisen that the importance of
(long-chain) fatty acids extends beyond their well-known functions
as metabolic substrate and constituent of complex lipids (e.g. in
biological membranes) in that fatty acids also modulate protein
function and gene expression. Important steps in this recognition
were made (i) with the identification of membrane-associated and
cytoplasmic proteins functioning in the uptake and transport of
fatty acids [14], and (ii) with the discovery of various isoforms of the
nuclear receptor subfamily of PPARs which are activated by fatty
acids and selected fatty acid metabolites as primary ligands [cf.
36,52]. In both these fields, dr. Paul A. Grimaldi hasmade significant
contributions in that with his team he was the first to show the
important role of the membrane protein CD36/SR-B2 in adipocyte
differentiation [13] and to demonstrate the existence of a third
isoform of the PPAR family, i.e., PPARb/d [42]. Both discoveries were
made in the early 90s and have triggered much research activity in
various preclinical and clinical laboratories. Specifically, both CD36/
SR-B2 and PPARb/d have emerged as potential therapeutic targets
in a range of metabolic diseases, in particular for metabolic syn-
drome [41,63,64].
Targeting CD36/SR-B2 could help normalize fatty acid meta-
bolism in cardiac and skeletal muscle of obese and/or insulin
resistant subjects thereby limiting the cardiovascular complications
associated with these conditions [24]. Activation of PPARb/d by
synthetic agonists has been found to promote fatty acid oxidationin several tissues such as skeletal muscle and brown adipose tissue
[65]. However, reported positive actions of PPAR agonists on blood
lipids, whole-body insulin resistance, and obesity show appreciable
side-effects, although less for PPARb/d agonists than for agonists of
the isoforms PPARa and PPARg. Taken together, additional insight
into the functioning of the PPARs and the cellular uptake, transport
and, hence, biological availability of their primary ligands, i.e., long-
chain fatty acids, under physiological and pathophysiological cir-
cumstances is needed in order to better design strategies for
therapeutic intervention.
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